Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Dapagliflozin Monotherapy in Japanese Subjects With Type 2 Diabetes Mellitus
jRCT2080220880Phase 2
- Sponsor
- AstraZeneca
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Dapagliflozin monotherapy with Placebo (2 arms). Primary endpoint: Primary efficacy and safety endpoints (unspecified).
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080220880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220880.